| Identification | Back Directory | [Name]
Carbazeran citrate | [CAS]
153473-94-0 | [Synonyms]
Carbazeran citrate
Ethyl 1-(6,7-dimethoxy-1-phthalazinyl)-4-piperidinyl carbamate citrate | [Molecular Formula]
C24H32N4O11 | [MDL Number]
MFCD26792564 | [MOL File]
153473-94-0.mol | [Molecular Weight]
552.54 |
| Hazard Information | Back Directory | [Uses]
Carbazeran (citrate), a potent phosphodiesterase inhibitor, is aldehyde oxidase substrate. Carbazeran (citrate) can be used for the research of metabolic disease[1]. | [in vivo]
Carbazeran (10 mg/kg; p.o.) (citrate) of the unmetabolized in samples from humanized-liver mice, the mean plasma concentrations are lower than in those from control mice for 0.5~4 hours after oral administration[1].
Oral administration of carbazeran (citrate) to guinea pigs has reportedly resulted in large kinetic deuterium isotope effects on the AUC and Cmax, without a change of systemic half-life[1]. | Animal Model: | Mice[1] | | Dosage: | 10 mg/kg | | Administration: | P.o. | | Result: | The mean plasma concentrations were lower than in those from control mice for 0.5~4 hours after oral administration. |
| [References]
[1] Uehara S, et al. Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes. Drug Metab Dispos. 2020;48(7):580-586. DOI:10.1124/dmd.120.091090 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|